AFP and neoplasm: In atezo/bev therapy for unresectable HCC, the change in AFP levels at 3 weeks in patients with baseline AFP level ≥ 20 ng/mL and baseline DCP level or tumor burden in those with AFP level < 20 ng/mL were found to predict treatment response.